For decades, medicine drew a quiet line at age fifty, assuming that cancers arriving later in life were the work of time rather than inheritance. A sweeping study of nearly forty thousand patients at Memorial Sloan Kettering Cancer Center has shown that line to be more habit than truth: nearly a third of those carrying inherited cancer variants were older than fifty, and would have been passed over entirely by current screening practice. The findings, published in Cancer Discovery, invite oncology to reconsider what it means to know a patient fully — not only for their own treatment, but for t
Study Challenges Age 50 Cutoff for Cancer Genetic Testing
Hereditary cancer can occur at any age
Mark
So the study tested everyone, regardless of age, and found that 72 percent of patients with inherited cancer variants would have been missed by the current standard practice. That's a huge number. Why has the age 50 cutoff persisted for so long?
Mimi
The logic was straightforward: younger patients with cancer are more likely to have inherited the disease, while older patients are more likely to have developed it through accumulated mutations over time. It made intuitive sense, and it also served as a practical gatekeeper—you can't test everyone, so you test the group most likely to benefit. But the study shows that inherited variants are far more common in older patients than anyone expected.
Luke
I want to be careful here. The study found that 16.3 percent of all patients had at least one pathogenic variant. But how many of those variants actually matter clinically? The researchers distinguish between high-penetrance, moderate-penetrance, and low-penetrance variants. The high- and moderate-penetrance variants—the ones with real implications for treatment or family risk—occurred in about 9.7 percent of all patients. That's still significant, but it's a different number than the headline.
Mimi
That's fair. And the prevalence does drop with age. In late-onset cancers, only 2.6 percent of patients carried high- or moderate-penetrance variants, compared to 9.1 percent in early-onset. So the age-based approach wasn't entirely wrong—it was just too blunt.
Mark
But even 2.6 percent of older patients is a lot of people if you're talking about a national scale. And the study says cascade testing of relatives is severely underutilized. If you identify one person with a hereditary variant, you can test their siblings, parents, children—people who might prevent cancer entirely through surveillance or preventive surgery.
Luke
True, but that assumes cascade testing is actually happening and that people want to know. The study doesn't tell us how many of the 4,601 older patients who carried variants were actually informed, or whether their relatives were offered testing. It's one thing to say universal testing should happen; it's another to implement it and ensure the results lead to action.
Mimi
That's exactly what Stadler was pointing to when she said cascade testing remains one of the most underused opportunities in cancer prevention. The infrastructure and the cultural practice aren't there yet. But the study is making the case that they should be.
Mark
One more thing—the study was done at a single major cancer center, and the population was predominantly European and Ashkenazi Jewish ancestry. Does that limit how much we can generalize from these findings?
Luke
It does. Different populations may have different frequencies of certain variants, and a tertiary cancer center may see a different mix of cancer types and stages than a community hospital. The findings are strong within this cohort, but we'd want to see this replicated in more diverse settings before declaring it a universal truth.
Mimi
Fair point. But the direction is clear: age alone is not a reliable predictor of who carries inherited cancer risk. That's a meaningful shift in how we should think about screening.
O Pulso
- The standard age-fifty cutoff for genetic cancer screening has been quietly failing patients for years, missing 72 percent of those who carry inherited cancer variants.
- More than 4,600 patients over fifty were found to harbor pathogenic genetic variants — people whose hereditary risk would have gone undetected and unaddressed under current guidelines.
- The inherited variants at stake are not merely diagnostic footnotes; they can directly shape treatment decisions and signal elevated cancer risk to siblings, children, and other relatives.
- Cascade testing — screening family members once a hereditary variant is identified — remains dramatically underused, leaving a clear prevention opportunity largely untaken.
- Researchers at Memorial Sloan Kettering are calling for universal genetic testing of all cancer patients regardless of age, though questions of cost, logistics, and insurance coverage remain unresolved.
For decades, medicine drew a quiet line at age fifty, assuming that cancers arriving later in life were the work of time rather than inheritance. A sweeping study of nearly forty thousand patients at Memorial Sloan Kettering Cancer Center has shown that line to be more habit than truth: nearly a third of those carrying inherited cancer variants were older than fifty, and would have been passed over entirely by current screening practice. The findings, published in Cancer Discovery, invite oncology to reconsider what it means to know a patient fully — not only for their own treatment, but for the generations connected to them.
A study of nearly forty thousand cancer patients at Memorial Sloan Kettering Cancer Center has challenged one of oncology's long-standing assumptions: that older patients rarely carry inherited cancer risk worth testing for. Using the MSK-IMPACT assay to screen blood and saliva samples for 94 known germline variants, researchers found that 16.3 percent of all patients carried at least one inherited variant linked to cancer. Of those, 4,601 were over fifty — the current threshold for routine screening — meaning the age-based approach would have missed 72 percent of carriers entirely.
The reasoning behind the fifty-year cutoff had always been intuitive: late-onset cancers seemed more likely to reflect accumulated cellular damage than inherited flaws. But the data complicated that picture. Even when researchers redefined early, average, and late onset by cancer type rather than a blanket age, inherited variants with direct treatment implications appeared across all groups — 9.1 percent in early-onset cases, 5.5 percent in average-onset, and 2.6 percent in late-onset cancers. Altogether, roughly one in ten patients carried variants that could meaningfully influence their care.
Dr. Zsofia K. Stadler, clinical director of the Clinical Genetics Service and co-author of the study, described the age cutoff as an arbitrary gatekeeper obscuring real hereditary risk. Beyond individual treatment, identifying these variants opens the door to cascade testing — screening relatives who may carry the same mutation and face their own elevated risk. That tool, Stadler noted, remains one of the most underutilized in cancer prevention, with only a minority of eligible family members currently screened.
Dr. Luis A. Diaz Jr., head of Solid Tumor Oncology and co-corresponding author, argued that hereditary cancer recognizes no age boundary, and that genetic testing should be standard for every cancer patient. The study's limitations — a single institution, a predominantly European and Ashkenazi Jewish cohort — temper the universality of its conclusions. But its central finding is difficult to dismiss: the age-based cutoff was never a scientific threshold, only a convenient one, and it has been leaving patients and their families without information that could change their lives.
A study of nearly 40,000 cancer patients at Memorial Sloan Kettering Cancer Center has upended a decades-old screening practice: the assumption that only younger patients need genetic testing for inherited cancer risk. The research, published in Cancer Discovery, found that when all patients were tested regardless of age, 16.3 percent carried at least one inherited genetic variant linked to cancer—and crucially, 4,601 of those patients were over 50, the current cutoff for routine screening. That means the standard age-based approach would have missed 72 percent of all patients carrying these variants.
The logic behind the age 50 cutoff seemed reasonable enough: cancers diagnosed later in life were thought to be less likely caused by inherited genetic flaws and more likely the result of accumulated damage over time. But the data suggested otherwise. Using the MSK-IMPACT assay to test blood or saliva samples from all 39,184 patients for 94 known germline pathogenic variants, researchers found that while early-onset cancers did carry a higher burden of these variants—18.4 percent compared to 12.3 percent in late-onset cases—the absolute numbers told a different story. Older patients still harbored substantial genetic risk, particularly variants that could guide treatment decisions or alert family members to their own cancer predisposition.
Dr. Zsofia K. Stadler, clinical director of the Clinical Genetics Service at Memorial Sloan Kettering and co-author of the study, described the current practice as a gatekeeper that obscures inherited cancer risk. The researchers wanted to know how much hereditary cancer risk was being missed by relying on an arbitrary age threshold. When they reclassified cancers by type—defining early-, average-, and late-onset based on the typical age of diagnosis for each specific cancer rather than a blanket age 50 cutoff—the prevalence of high- and moderate-penetrance variants (those most likely to affect treatment or family risk) was still substantial across all groups: 9.1 percent in early-onset, 5.5 percent in average-onset, and 2.6 percent in late-onset cancers. Taken together, about 9.7 percent of all patients carried variants with direct implications for how they might be treated.
The practical value of identifying these variants extends beyond the individual patient. Knowing a person carries an inherited cancer predisposition variant opens the door to cascade testing—screening relatives who may carry the same mutation and therefore face elevated cancer risk themselves. This is where prevention becomes possible. Yet cascade testing remains one of the most underutilized tools in cancer prevention, Stadler noted. Once a hereditary variant is identified, testing relatives becomes highly targeted and informative, yet only a minority of eligible family members currently undergo screening. Universal genetic testing could change that calculus, making it routine to identify at-risk relatives and offer them surveillance or preventive measures.
Dr. Luis A. Diaz Jr., head of Solid Tumor Oncology at Memorial Sloan Kettering and co-corresponding author, argued plainly for a shift in standard practice: hereditary cancer can occur at any age, and genetic testing should be considered for every patient diagnosed with cancer, regardless of age. The study demonstrated that age at diagnosis is an insufficient filter—it misses too many people who could benefit from knowing their genetic status, both for their own treatment and for their families' health.
The research does carry limitations worth noting. It was conducted at a single major cancer center, and the patient population was predominantly of European and Ashkenazi Jewish ancestry, with some cancer types over- or underrepresented in the cohort. Those constraints mean the findings may not apply uniformly across all populations and settings. Still, the core finding stands: the current age-based screening approach is leaving substantial numbers of patients and their relatives without critical genetic information. Whether oncology practices will move toward universal testing—and whether insurance and healthcare systems will support the cost and logistics of doing so—remains an open question. But the data now suggest that the old cutoff was never more than a convenient boundary, not a scientific one.
Citações Notáveis
The current standard practice is, in many ways, a gatekeeper for genetic testing. Our study aimed to assess how much inherited cancer risk we miss when we rely too heavily on age at diagnosis.— Dr. Zsofia K. Stadler, Memorial Sloan Kettering Cancer Center
Hereditary cancer can occur at any age, and we should move toward a new standard in which genetic testing is considered for every patient diagnosed with cancer, regardless of age.— Dr. Luis A. Diaz Jr., Memorial Sloan Kettering Cancer Center
Quer a matéria completa?
Leia o original em American Association for Cancer Research ↗
Health & Medicine